Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding Apogee Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 174 | 2 | 207 | +35 |
| Shares | 59.6M | 32.7K | 69.8M | +10.2M (+17.2%) |
| Value | $2.37B | $1.30M | $5.27B | +$2.90B (+122.6%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (53)
Institutions that held Apogee Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (18)
Institutions that held Apogee Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Jefferies Financial Group Inc. | 568,084 | $22.6M |
| Commodore Capital LP | 290,000 | $11.5M |
| Tang Capital Management LLC | 200,000 | $7.95M |
| Exome Asset Management LLC | 94,400 | $3.75M |
| Balyasny Asset Management LLC | 72,348 | $2.87M |
| Diadema Partners LP | 64,250 | $2.55M |
| Aquatic Capital Management LLC | 39,332 | $1.56M |
| ExodusPoint Capital Management, LP | 37,535 | $1.49M |
| Prelude Capital Management, LLC | 26,241 | $1.04M |
| Natixis Advisors, L.P. | 12,475 | $496.0K |
| Family Management Corp | 5,589 | $222.1K |
| Caption Management, LLC | 4,800 | $190.7K |
| Caitong International Asset Management Co., Ltd | 97 | $3.85K |
| Washington Trust Advisors, Inc. | 96 | $3.81K |
| Rise Advisors, LLC | 16 | $636 |
| Federation des caisses Desjardins du Quebec | 10 | $397 |
| Principal Securities, Inc. | 5 | $199 |
| Montag A & Associates Inc | 4 | $159 |
Not filed for Q4 2025 yet (2)
Institutions that held Apogee Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| AXA Investment Managers S.A. | 24,554 | $975.5K |
| Glenmede Investment Management, LP | 8,127 | $322.9K |